Covid-19 roundup: Sinopharm touts 'bet­ter than ex­pect­ed' PhI­II vac­cine da­ta; Af­ter Pfiz­er/BioN­Tech, Rus­sia claims vac­cine is 92% ef­fec­tive on slim­mer ev­i­dence

On the heels of ground­break­ing Covid-19 vac­cine da­ta from Pfiz­er and BioN­Tech — and Rus­sia’s claims that its Sput­nik V is just as good — Chi­na’s Sinopharm said late-stage da­ta from its can­di­dates are “bet­ter than ex­pect­ed.”

It’s un­clear what Sinopharm is bas­ing its char­ac­ter­i­za­tion on. In a state­ment post­ed on WeChat, the state-owned com­pa­ny not­ed that its tri­als are in fi­nal stages, with over 50,000 vol­un­teers en­rolled in the Unit­ed Arab Emi­rates, Bahrain, Egypt, Jor­dan, Mo­roc­co, Pe­ru, Ar­genti­na and oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.